Meeting Banner
Abstract #2477

Amide CEST at 7T: A possible biomarker for response to neoadjuvant chemotherapy in breast cancer

Erwin Krikken1, Moritz Zaiss2, Vitaliy Khlebnikov1, Hanneke W.M. van Laarhoven3, Dennis W.J. Klomp1, and Jannie P. Wijnen1

1Radiology, University Medical Center Utrecht, Utrecht, Netherlands, 2Deutsches Krebforschungszentrum, Heidelberg, Germany, 3Medical Oncology, Academic Medical Center Amsterdam, Amsterdam, Netherlands

Neoadjuvant chemotherapy has an important role in the treatment of breast cancer and the need for early detection of treatment response is high. As a non-invasive method able to predict treatment response is lacking, we investigated the feasibility of using amide CEST MRI at 7T as a biomarker. Six patients were included after informed consent was given. The ATP signal was robust and repeatedly detectable in the same patient. Significant differences were seen in amide signal before and after the first cycle of chemotherapy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here